日韩精品久久无码中文字幕,色欲av无码一区二区三区,少妇无码一区二区三区,精品久久久久国产免费

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73191SLC34A2-ROS1/BaF3

SLC34A2-ROS1/BaF3
名稱 SLC34A2-ROS1/BaF3
型號 CBP73191
報價
特點 SLC34A2-ROS1/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO;
  • 詳細內(nèi)容
CBP73191
I. Introduction

Cell Line Name:

SLC34A2-ROS1/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).

In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).

Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.

ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).


III. Representative Data

1. WB of SLC34A2-ROS1 expression

CBP73191 WB.png



2.Sanger Sequencing of SLC34A2-ROS1 Fusion

CBP73191 sanger.png

2. Anti-proliferation assay

CBP73191 fig.png

Figure 3. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1/BaF3 Stable Cell Line.


如果你對CBP73191SLC34A2-ROS1/BaF3感興趣,想了解更詳細的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
精品无码三级在线观看视频| 国产99久久久国产精品~~牛| 日韩AV高清在线观看| 人善交videos欧美3d| 含一整夜 好涨h| 国产AV人人夜夜澡人人爽| 日日碰狠狠躁久久躁综合网| 无码国产69精品久久久久网站| 日韩欧美激情免费a片影院卜| 公的粗大挺进了我的密道| 护士奶头又白又大又好摸视频| 欧美性大战久久久久久久| 国产女人aaa级久久久级| 亚洲成色WWW久久网站| 免费观看黄色电影| 内射人妻少妇无码一本一道| 欧美大成色WWW永久网站婷| 男生女生向前冲第六季| 真人做爰高潮全过程毛片| 雯雯在工地被灌满精在线播放| 无码少妇精品一区二区免费动态| 黑人40厘米全部进去a片| 国产午夜亚洲精品不卡| 亚洲性爱视频| 亚洲av片不卡无码久久| 国产精品成人精品久久久| 亚洲国产精品成人天堂| 国产精品免费精品自在线观看| 辽宁少妇高潮45分钟| 曰本女人与公guo交酡视频a片| 午夜福利电影| 狠狠色丁香婷婷久久综合麻豆| 日本护士xxxx做爰| 亚洲综合欧美色五月俺也去| 亚洲精品色情app在线下载观看| 精品无码av一区二区三区不卡| 久久精品国产亚洲AV麻豆| 国产精品久久毛片a片| 女女女女bbbbbb毛片在线| 国产露脸精品产三级国产av| 俄罗斯少妇性做爰片|